The Risk of Recurrence in Breast Cancer Patients Treated with Tamoxifen: Polymorphisms of CYP2D6 and ABCB1
- 20 December 2011
- journal article
- Published by Springer Nature in The AAPS Journal
- Vol. 14 (1) , 52-59
Abstract
CYP2D6plays a major role in the metabolism of tamoxifen, and polymorphism of P-glycoprotein has been associated with resistance of many drug therapies. This study investigates the clinical impact of...Keywords
This publication has 38 references indexed in Scilit:
- Endoxifen, the Active Metabolite of Tamoxifen, Is a Substrate of the Efflux Transporter P-Glycoprotein (Multidrug Resistance 1)Drug Metabolism and Disposition, 2011
- Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patientsBritish Journal of Clinical Pharmacology, 2011
- MDR1 (C3435T) polymorphism: relation to the risk of breast cancer and therapeutic outcomeThe Pharmacogenomics Journal, 2009
- No Association Between CYP2D6*10 Genotype and Survival of Node-negative Japanese Breast Cancer Patients Receiving Adjuvant Tamoxifen TreatmentJapanese Journal of Clinical Oncology, 2009
- The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifenBreast Cancer Research and Treatment, 2006
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defenseToxicology and Applied Pharmacology, 2005
- CYP2D6 Genotype, Antidepressant Use, and Tamoxifen Metabolism During Adjuvant Breast Cancer TreatmentJNCI: Journal of the National Cancer Institute, 2005
- Beta-blockers in heart failure. 2. Mode of actionJournal of Clinical Pharmacy and Therapeutics, 2001
- c-erbB-2 (HER-2/neu) protein and drug resistance in breast cancer patients treated with induction chemotherapyInternational Journal of Cancer, 1999